Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
NeOnc (NASDAQ: NTHI) is entering one of the most significant periods after securing its second IND from the UAE
-
NeOnc Technologies Receives UAE IND Approval for NEO100, Expanding Global Development Ahead of Anticipated Phase 2 Data Milestone
-
NeOnc(NASDAQ: NTHI) is rapidly emerging as a development-stage neuro-oncology innovator
-
NASHVILLE, Tenn. and PHILADELPHIA, Penn., June 16, 2026 (GLOBE NEWSWIRE) -- Behavioral Health Insights (BHI), a leading provider of clinically accurate, comprehensive behavioral health real-world...
-
NeOnc Technologies Secures UAE IND Approval for NEO212 Following Successful Phase 1 Completion, Advancing Toward Global Phase 2 Development
-
First patient dosed in FPWR-supported Phase 2a trial of CSTI-500 for hyperphagia and neurobehavioral symptoms in PWS.
-
Chris Persel of Centre for Neuro Skills receives the first-ever Enduring Contributions Award from ABAI's Brain Injury Special Interest Group.
-
NeOnc (NASDAQ:NTHI) is developing therapies and delivery technologies targeting aggressive brain cancers and CNS-related conditions, and could be part of t
-
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3...
-
Phase 2 and Phase 3 trials are reshaping expectations across obesity, oncology, gene editing, autoimmune disease, and neurological disorders.